This Day On The Street
Continue to site right-arrow
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
Stocks Under $10 with 50-100% upside potential - 14 days FREE!

NexMed, Inc. Announces Results Of Special Meeting Of Stockholders, Including Name Change To Apricus Biosciences

NexMed, Inc. (Nasdaq:NEXM), backed by a revenue generating CRO business and seeking to leverage its proprietary, multi-route NexACT ® drug delivery technology and internal pipeline through out-licensing arrangements and partnerships, announced the results of its Special Meeting of Stockholders, held today, Friday, September 10, 2010.

At the Special Meeting, the Stockholders of the Company approved, by an affirmative majority vote, to change the name of the Company from NexMed, Inc. to Apricus Biosciences, Inc. (“Apricus Bio”), effective September 10, 2010. The name change was brought on to reflect the broader focus of the Company’s development programs. The Company’s common stock will commence trading under the symbol, NASDAQ: APRI, effective at the open of the market on Tuesday, September 14, 2010.

Dr. Bassam Damaj, President and Chief Executive Officer of NexMed, commented, “Beginning with the acquisition of Bio-Quant by NexMed in late 2009, we have undertaken a number of positive changes that are expected to reshape the Company over the long-term. In particular, we have expanded our product pipeline, re-energized the development of the NexACT technology as a drug delivery platform and have begun active licensing efforts for both proprietary programs, as well as third party programs enhanced with the NexACT technology. Additionally, we have leveraged Bio-Quant’s CRO capabilities to help advance new applications for NexACT. The rebranding of the Company at this time is part of our broader effort to alert potential development partners and the investment community of our new business model.”

In connection with the Company’s name change, management expects to launch its new website, on Tuesday, September 14, 2010.

In addition, the Stockholders approved, by an affirmative majority vote, to increase the number of shares of Common Stock authorized for issuance by the Company from 18,000,000 shares to 75,000,000 shares.

About Apricus Biosciences

Backed by a solid, revenue generating CRO business, Bio-Quant, Inc., and its NexMed USA subsidiary, Apricus Bio has leveraged the flexibility of its proven NexACT ® drug delivery technology to enable multi-route administration of new and improved compounds across numerous therapeutic classes. Future growth is expected to be driven primarily through out-licensing of this technology for the development and commercialization of such compounds to pharmaceutical and biotechnology companies, worldwide. Concurrently, the Company is seeking to monetize its existing product pipeline, including compounds from pre-clinical through Phase 3, currently focused on dermatology, sexual dysfunction and cancer. For further information on the Company and its subsidiaries, visit

1 of 2

Select the service that is right for you!

Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!


DOW 17,880.83 +76.03 0.43%
S&P 500 2,071.75 +1.10 0.05%
NASDAQ 4,770.7030 +5.3230 0.11%

Brokerage Partners

Rates from

  • Mortgage
  • Credit Cards
  • Auto

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs